Acute Graft-Versus-Host Disease
31
7
10
6
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
12.9%
4 terminated out of 31 trials
60.0%
-26.5% vs benchmark
10%
3 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (31)
Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
MAGIC Ruxolitinib for aGVHD
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD)
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Universal CNK-UT Therapy for Refractory aGVHD
Tissue-resident Immune Cell Subsets in aGVHD
A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation
Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI
Donor Neutrophil Subsets to Predict the Risk of aGVHD
Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.